HindustanTimes Wed,16 Apr 2014

Bayer loses plea against cheap Indian cancer drug

AP  New Delhi, March 05, 2013
First Published: 11:54 IST(5/3/2013) | Last Updated: 12:04 IST(5/3/2013)

India's patent appeals office has rejected international drug maker Bayer AG's plea to stop an Indian company from manufacturing a cheaper generic version of a patented cancer drug.


The ruling passed on Monday is being hailed as an important precedent for getting inexpensive life-saving drugs to the poor.

The German company had filed an appeal against the Indian patents office's decision last year to grant a compulsory license to local drug manufacturer Natco Pharma to produce a generic version of its kidney and liver cancer treatment Nexavar.

Bayer sells a one month supply of the drug for about $5,600. Natco's version would cost Indian patients $175 a month.

more from New Delhi

Delhi: HIV patient gets 7 years' jail for robbery

A Delhi court has sentenced an HIV-positive man and his wife to seven years in jail for robbery and house trespassing. The court said there were no grounds for leniency on account of health since such crimes were on the rise and needed to be curbed.

Most Popular
Copyright © 2014 HT Media Limited. All Rights Reserved